- Work address:
- Cancer Research UK Cambridge Institute University of Cambridge Li Ka Shing Centre Robinson Way Cambridge CB2 0RE
-
Author Correction: High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer.
E-pub date: 14 Nov 2022Journal name: Nat Commun
Clonal somatic copy number altered driver events inform drug sensitivity in high-grade serous ovarian cancer
E-pub date: 26 Oct 2022Journal name: Nat Commun
Identification of a molecularly-defined subset of breast and ovarian cancer models that respond to WEE1 or ATR inhibition, overcoming PARP inhibitor resistance.
E-pub date: 14 Oct 2022Journal name: Clin Cancer Res
- Research Integrity Conflict of Interest Disclosure:
- Last revised:
- 11/11/2022
Company Active Research funding Ownership Royalty payments Commitment to carry out work for a fee Ad hoc reimbursed work Travel Gifts/ other Astra Zeneca No Yes No No Yes No No No Roche No Yes No No No No No No Genentech No Yes No No No No No No Servier No Yes No No No No No No Varsity Pharmaceuticals Yes Yes No No No No No No
Tweets
© 2022 University of Cambridge
This Site Uses Cookies
We may use cookies to record some preference settings and to analyse how you use our web site. We may also use external analysis systems which may set additional cookies to perform their analysis.These cookies (and any others in use) are detailed in our site privacy and cookie policies and are integral to our web site. You can delete or disable these cookies in your web browser if you wish but then our site may not work correctly.